TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $6,475,280.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $8,566,679.81. The sale was disclosed in a filing with the SEC, which is available at this link.

TransMedics Group Stock Performance

Shares of TMDX opened at $127.99 on Friday. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock has a market cap of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. The business’s 50 day moving average price is $85.54 and its 200-day moving average price is $77.08. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $129.66.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. The firm’s quarterly revenue was up 132.9% compared to the same quarter last year. Equities research analysts anticipate that TransMedics Group, Inc. will post 0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently bought and sold shares of the company. FMR LLC raised its holdings in TransMedics Group by 42.5% in the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after buying an additional 1,407,171 shares during the last quarter. Eventide Asset Management LLC raised its holdings in TransMedics Group by 1,271.7% in the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after acquiring an additional 857,895 shares during the last quarter. Mackenzie Financial Corp bought a new position in TransMedics Group in the 4th quarter valued at approximately $35,804,000. Wasatch Advisors LP purchased a new stake in TransMedics Group during the 1st quarter valued at $32,162,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after purchasing an additional 363,012 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on TMDX. Piper Sandler reiterated an “overweight” rating and set a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday. Oppenheimer upped their target price on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley raised their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. upped their price target on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Canaccord Genuity Group increased their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.